Stock Analysis

Allergy Therapeutics First Half 2024 Earnings: UK£0.006 loss per share (vs UK£0.013 loss in 1H 2023)

Simply Wall St

March 29, 2024

Allergy Therapeutics (LON:AGY) First Half 2024 Results

Key Financial Results

Revenue: UK£33.6m (down 16% from 1H 2023).
Net loss: UK£15.7m (loss widened by 84% from 1H 2023).
UK£0.006 loss per share.

earnings-and-revenue-history — AIM:AGY Earnings and Revenue History March 29th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Allergy Therapeutics shares are up 9.1% from a week ago.

Risk Analysis

It is worth noting though that we have found 4 warning signs for Allergy Therapeutics (3 are a bit unpleasant!) that you need to take into consideration.

Valuation is complex, but we're helping make it simple.

Find out whether Allergy Therapeutics is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.